The Allergic Rhinitis Drugs Market Will Reach $16,500m in 2026

Monday 31 October 2016, Amsterdam

Market Research Report Press Release A new report, now available on ASDReports, predicts that the Allergic Rhinitis Drugs market will reach $16,500m in 2026. This forecast and others appear in - Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. published in September 2016.

The Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co., report examines the current and future trends in the Allergic Rhinitis Drugs Market with particular focus on recent pivotal developments in the sector involving patent expires, OTC swithces, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the allergic rhinitis drugs market.

Allergic Rhinitis Drugs are used to treat and manage allergic rhinitis symptoms. This is irritation and inflammation of the lining of the nasal passages which is caused by an allergic reaction. The symptoms are sneezing, nasal congestions, itching and rhinorrhoea. Allergic Rhinitis is very common, leading to a large patient population.

The driving force behind growth in this market is the increasing prevalence of allergic rhinitis, new products launching onto the market and OTC switches. There is an increased demand for treatment of allergic rhinitis, as a result of climate change and industrialisation. The allergic rhinitis drugs market is increasingly expected to innovate in order to meet these demands in a safe manner, focusing intention on treatment rather than symptomatic relief.

In this report, we examine in detail the factors which are driving the Allergic Rhinitis Drugs Market growth, the key companies currently operating in the allergic rhinitis drugs market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of allergic rhinitis drugs.

The Allergic Rhinitis market segments examined in this report are: Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Intranasal Antihistamines. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

This report also provides an analysis of the current leading players in the Allergic Rhinitis Drugs Market. Historical financial performance is analysed, along with a breakdown of each company’s leading products and pipeline research, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.
Allergic Rhinitis Drugs Market Forecast 2016-2026

Allergic Rhinitis Drugs Market Forecast 2016-2026

Publish date : September 2016
Report code : ASDR-289343
Pages : 240

Global Allergic Rhinitis Drugs Market 2018-2028

Global Allergic Rhinitis Drugs Market 2018-2028

Publish date : August 2018
Report code : ASDR-466891
Pages : August 2018

ASDReports.com Media contact: S. Koopman - Marketing and Communications

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : stefan.koopman@asdreports.com

 back to News